From Our Partners
Wednesday, June 22, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Phase I Clinical Trial Unit for Infectious Disease Therapeutics

by Global Biodefense Staff
December 18, 2014

The National Institute of Allergy and Infectious Diseases (NIAID) has announced new contract awards to support the Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases.

Since Phase I studies are often on the critical path for product development of bacterial, viral, parasitic, and fungal countermeasures, the ability to prepare protocols and execute trials in a timely manner is important.  To help meet these goals and move promising candidates into the clinical pipeline in a timely manner, DMID initially awarded contracts for the Phase I Unit in 2008.

The current contract announcement is the result of a recompete of these program requirements to continue to provide NIAID with the infrastructure necessary for the design and conduct of Phase I clinical trials for therapeutics.

Awards were made to the following organizations, with a maximum value of $90,000,000:

  • Dynport Vaccine Company
  • Duke University
  • Clinical Research Management

The types of trials conducted or planned include first-in-human small molecule and monoclonal antibody trials, corrected QT interval (QTc) trials, and drug-drug interaction trials.

The contracts were awarded via Solicitation Number: RFP-NIAID-DMID-NIHAI2013178

From Our Partners
Tags: AwardsNIAID

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Biodefense Headlines – 16 June 2022

Biodefense Headlines – 16 June 2022

June 16, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC